Biomea Fusion announced Phase 1 trial results for BMF-650, an oral GLP-1 receptor agonist for obesity, showing consistent weight loss of 1.5% to 3.2% over 29 days across multiple dose groups with good tolerability and no serious side effects. The highest dose group achieved 6.1% weight loss with a rapid titration regimen, supporting potential for simplified dosing without increased gastrointestinal side effects. These early results validate the drug's design and support further development, with Biomea seeking partnerships for late-stage trials. The company remains focused on its diabetes drug icovamenib but sees BMF-650 as a promising obesity treatment candidate.
The Phase 1 trial results for Biomea Fusion's BMF-650 showed consistent weight loss of up to 6.1% in the highest dose group. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 14, 2026 03:02 WIB: out of 128 priced US health-sector stocks, 28 rose and 100 fell. Notable movers include HRTX at USD 0.39 with a 5.32% decline and 61% sell order activity, NUWE at USD 0.64 down 5.27% with 64% buy order activity, and TXG at USD 71.71 down 4.63% with 100% buy order activity and a typical hold time of 92 days.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
